FdaApplication
NDA 210365
Identifiers
- fda_app_no: NDA210365
Properties
| Property | Value |
|---|---|
| applicant_name | JAZZ PHARMACEUTICALS RESEARCH UK LTD |
| application_type | NDA |
| approval_date | 2018-09-28 |
Revenue by product
EPIDIOLEX
| Period | Revenue |
|---|---|
| Q2 2026 | $292.1M |
| Q1 2026 | $249.8M |
| Q4 2025 | $287.1M |
| Q3 2025 | $302.6M |
| Q2 2025 | $251.7M |
| Q1 2025 | $217.7M |
| Q4 2024 | $275.0M |
| Q3 2024 | $251.6M |
| Q2 2024 | $247.1M |
| Q1 2024 | $198.7M |
| Q4 2023 | $240.6M |
| Q3 2023 | $213.7M |
| Q2 2023 | $202.2M |
| Q1 2023 | $188.9M |
| Q4 2022 | $207.0M |
| Q3 2022 | $196.2M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| EPIDIOLEX | CANNABIDIOL | 100MG/ML | SOLUTION;ORAL |
1 product